Dimerix Limited (ASX:DXB)

Market Cap	254.54M
Revenue (ttm)	737.87K
Net Income (ttm)	-23.31M
Shares Out	559.43M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,404,434
Average Volume	1,832,173
Open	0.4950
Previous Close	0.4550
Day's Range	0.4800 - 0.5100
52-Week Range	0.3000 - 0.6650
Beta	0.73
RSI	57.64
Earnings Date	May 23, 2025

About Dimerix

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nina Webster
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: DXB

Financial Performance

In 2024, Dimerix's revenue was 583,478, an increase of 1486.10% compared to the previous year's 36,787. Losses were -17.08 million, 23.7% more than in 2023.